485 related articles for article (PubMed ID: 9064946)
1. [Differential therapy of cardiogenic shock with dopamine/milrinone in comparison with dopamine/dobutamine].
Meissner A; Schmelzle T; Simon R
Z Kardiol; 1996 Nov; 85(11):839-46. PubMed ID: 9064946
[TBL] [Abstract][Full Text] [Related]
2. [Additive effects of milrinone and dobutamine in severe heart failure].
Meissner A; Herrmann G; Gerdesmeyer L; Simon R
Z Kardiol; 1992 May; 81(5):266-71. PubMed ID: 1621407
[TBL] [Abstract][Full Text] [Related]
3. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.
Colucci WS; Wright RF; Jaski BE; Fifer MA; Braunwald E
Circulation; 1986 Mar; 73(3 Pt 2):III175-83. PubMed ID: 3510774
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of cardiogenic shock with dobutamine and nitroglycerin].
Bussmann WD; Wehrheim HG
Dtsch Med Wochenschr; 1983 Aug; 108(34):1273-80. PubMed ID: 6411441
[TBL] [Abstract][Full Text] [Related]
5. Dopamine may preserve the myocardial oxygen balance better than dobutamine when administered with milrinone.
Takamatsu I; Karasawa F; Okuda T
Can J Anaesth; 2002 Nov; 49(9):968-72. PubMed ID: 12419727
[TBL] [Abstract][Full Text] [Related]
6. [Hemodynamics with dobutamine and milrinone in patients with severe heart failure in an intra-individual comparison].
Mager G; Klocke RK; Volkmann A; Kux A; Höpp HW; Hilger HH
Z Kardiol; 1991 Feb; 80(2):149-57. PubMed ID: 2058247
[TBL] [Abstract][Full Text] [Related]
7. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
[TBL] [Abstract][Full Text] [Related]
8. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure.
Monrad ES; Baim DS; Smith HS; Lanoue AS
Circulation; 1986 Mar; 73(3 Pt 2):III168-74. PubMed ID: 3510773
[TBL] [Abstract][Full Text] [Related]
9. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine].
Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M
Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic equivalence of automated nitroglycerin- and nitroprusside-infusions combined with dobutamine for augmentation of cardiac output in patients following aorta coronary bypass-operation.
Pomer S; Sarai K; Krause E; Satter P
Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):602-7. PubMed ID: 6437993
[TBL] [Abstract][Full Text] [Related]
11. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
El Mokhtari NE; Arlt A; Meissner A; Lins M
Eur J Med Res; 2007 Nov; 12(11):563-7. PubMed ID: 18024265
[TBL] [Abstract][Full Text] [Related]
12. A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.
Pflugfelder PW; O'Neill BJ; Ogilvie RI; Beanlands DS; Tanser PH; Tihal H; Mizgala HF; Fitchett DH; Kostuk WJ
Can J Cardiol; 1991; 7(1):5-10. PubMed ID: 2025794
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the hemodynamic effects of milrinone with dobutamine in patients after cardiac surgery.
Feneck RO; Sherry KM; Withington PS; Oduro-Dominah A;
J Cardiothorac Vasc Anesth; 2001 Jun; 15(3):306-15. PubMed ID: 11426360
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact.
Yamani MH; Haji SA; Starling RC; Kelly L; Albert N; Knack DL; Young JB
Am Heart J; 2001 Dec; 142(6):998-1002. PubMed ID: 11717603
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity and prediction of hemodynamic responses to dobutamine in patients with septic shock.
Jellema WT; Groeneveld AB; Wesseling KH; Thijs LG; Westerhof N; van Lieshout JJ
Crit Care Med; 2006 Sep; 34(9):2392-8. PubMed ID: 16849997
[TBL] [Abstract][Full Text] [Related]
16. Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal.
Monrad ES; Baim DS; Smith HS; Lanoue AS; Silverman KJ; Gervino EV; Grossman W
Circulation; 1986 Mar; 73(3 Pt 2):III205-12. PubMed ID: 3510776
[TBL] [Abstract][Full Text] [Related]
17. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
Travill CM; Pugh S; Noble MI
Clin Ther; 1994; 16(5):783-92. PubMed ID: 7859237
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure.
Mager G; Klocke RK; Kux A; Höpp HW; Hilger HH
Am Heart J; 1991 Jun; 121(6 Pt 2):1974-83. PubMed ID: 1852090
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic effects of milrinone with and without a bolus loading infusion.
Baruch L; Patacsil P; Hameed A; Pina I; Loh E
Am Heart J; 2001 Feb; 141(2):266-73. PubMed ID: 11174341
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and therapeutic effects of intravenous dopamine.
Théroux P; Mizgala HF; Bourassa MG
Can Med Assoc J; 1977 Mar; 116(6):645-8. PubMed ID: 608165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
